Investigational drug · Phase 2
BGM1812
Also called: plcaebo
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Overweight or Obese Participants Without Diabetes.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "BGM1812"
First trial start
2026
Nov 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BGM1812", any sponsor or status.
Conditions studied
As listed on its trial records.
- Overweight or Obese Participants Without Diabetes
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "BGM1812" as an intervention, largest first.
- A Study to Evaluate Efficacy and Safety of BGM1812 Injection in Overweight or Obese Participants Without DiabetesPivotal-lookingNot yet recruiting
BrightGene Bio-Medical Technology Co., Ltd.Industry
NCT07918625 · 160 participants (planned) · Start Nov 30, 2026 · Primary completion Aug 1, 2027
Drug: BGM1812 injection / plcaebo; BGM1812 injection / plcaebo and 2 more · For: Overweight or Obese Participants Without Diabetes
Sites: Changsha, China
- A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese ParticipantsCompleted
BrightGene Bio-Medical Technology Co., Ltd.Industry
NCT07294235 · 60 participants · Start Dec 5, 2025 · Primary completion Jun 5, 2026
Drug: BGM1812; Placebo and 2 more · For: Overweight or Obesity
Sites: Kunming, China
BrightGene Bio-Medical Technology Co., Ltd.Industry
NCT07224399 · 60 participants · Start Oct 9, 2025 · Primary completion Jul 17, 2026
Drug: BGM1812; Placebo and 2 more · For: Healhty; Overweight or Obesity
Sites: Baltimore, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment.
Zong L, Zhang Z, Li X, et al. · J Med Chem 2025
Also in development for Overweight or Obese Participants Without Diabetes
- BGM0504Phase 35 trials
BrightGene Bio-Medical Technology Co., Ltd. · Type 2 Diabetes (T2DM), Overweight or Obese Participants Without Diabetes, Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.